Learn about cutting-edge science and gain life-enhancing insights.

News

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in…

News

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a…

News

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

–   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of…

News

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…

News

atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…

Articles

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal…

Press Inquiries

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Headquartered in Berlin, with offices in New York and London, our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life.

GET IN TOUCH
JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit